Compare Medpace Holdings Inc (MEDP) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Strategy Inc. — how do they compare? Medpace Holdings Inc trades at $611.72 (market cap $16.82B), while Strategy Inc. trades at $153.73 (market cap $60.40B). The key difference: Strategy Inc. is far larger — about 3.6× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Strategy Inc. for 112 Days on average.
| MEDP | MSTR | |
|---|---|---|
Market Cap | $16.82B | $60.40B |
Volume | 223,093 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $630.19 | $320.29 |
52-Week Low | $393.42 | $82.31 |
Typical Hold Time | 14 Days | 112 Days |
Enterprise Value | $16.44B | $79.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
MSTR trades at $151.89, down 0.96% on the day, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with a net income margin of -6,102.96% and three consecutive quarterly earnings misses. Despite negative profitability, analyst consensus remains bullish with a $253.36 price target, representing 67% upside potential from current levels. Recent news highlights Citigroup doubling its price target to $240 following a 35% monthly rally.
The outlook remains polarized between technical optimism and fundamental challenges. While technical indicators suggest continued momentum, the company's massive losses and negative cash flow from operations pose significant risks. Investors face the dilemma of strong Wall Street support against deteriorating financial performance, with the stock's fate closely tied to Bitcoin market movements despite being a traditional software company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
